Successful CAR-T cell therapy for end-stage multiple myeloma using advanced cellular product performed in Hong Kong

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first myeloma patient with this therapy, resulting in a very good response without severe complications. The expansion of this innovative treatment to myeloma patients offers new hope for those who have not responded to traditional treatment, marking a significant milestone in advancing health care in Hong Kong.

Facebook Comments